Though it’s a quiet week on the earnings front, there is plenty to read into on Wall Street this week. Here is what …
Healthcare analysts weigh in on pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) and liver disease firm Intercept Pharmaceuticals Inc (NASDAQ:ICPT).
Moving a pipeline drug from inception to commercialization can take years for biotech companies. Analysts weigh in on upcoming catalysts for Sarepta Therapeutics …
As Intercept Pharmaceuticals Inc (NASDAQ:ICPT) approaches a crucial date for FDA approval of a liver disease treatment and Rexahn Pharmaceuticals, Inc (NYSE:RNN) announces its YE15 earnings …
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, …
Background Shares in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) climbed as much as +31% on February 12th following a report from Reuters citing anonymous sources …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, …
Holiday sales, pipeline updates, and a tax credit extension mark this week’s earnings reports from Fitbit Inc (NYSE:FIT), First Solar, Inc. (NASDAQ:FSLR), Intercept …
The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that …
The New Year brings another turbulent season for biotech investors as top-line data continues to be released and the FDA’s approval process marches …
